*Corresponding Author: *Corresponding author: Prof. Mehri Kadkhodaee, Department of Physiology, Faculty of Medicine, Tehran University of Medical Sciences. Telephone: 00982188259862, Fax: 00982166419484, , Email:
kadkhodm@tums.ac.ir
Abstract
Recent publications have suggested renoprotective actions for erythropoietin in certain models of acute kidney injury. In a study by Rafieian-Kopaei et al., the effects of erythropoietin on amelioration of gentamicin-induced renal toxicity was investigated and renoprotective effect for Eprex, an analogue of erythropoietin was shown when the drug was given in combination with gentamicin. There has also been a protective effect when the drug was applied after gentamicin administration. Thus, the drug was effective even after induction of tubular damage which opens a very valuable window for its therapeutic actions. However, there are still needs for studies on the mechanisms which are involved in these protective actions
Implication for health policy/practice/research/medical education:
Eprex an erythropoietin analogue is a promising renoprotective drug to prevent or attenuate GM-induced tubular damage and introduces a novel therapeutic strategy for patients with renal tubular epithelial cell damage. However, there are still needs for studies on the mechanisms which are involved in these protective actions.
Please cite this paper as: Kadkhodaee M. Erythropoietin; bright future and new hopes for an old drug. J Nephropathology. 2012; 1(2): 81-82. DOI: 10.5812/nephropathol.7475